FOS and breast carcinoma: Since the transcriptional activities of NFκB and AP-1 complexes are not directly measurable in clinical breast cancer samples, prognostic signatures reflecting these activities would help to identify high-risk ER-positive breast cancers in need of more aggressive adjuvant therapy.